SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-3.32%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$306M
AUM Growth
+$306M
(-2%)
Cap. Flow
+$5.38M
Cap. Flow
% of AUM
1.76%
Top 10 Holdings %
Top 10 Hldgs %
51.08%
Holding
39
New
6
Increased
12
Reduced
17
Closed
1
Top Buys
| 1 |
Merck
MRK
|
$16M |
| 2 |
Thermo Fisher Scientific
TMO
|
$10.3M |
| 3 |
Labcorp
LH
|
$5.11M |
| 4 |
Avantor
AVTR
|
$5.02M |
| 5 |
DexCom
DXCM
|
$4.36M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$16.3M |
| 2 |
Edwards Lifesciences
EW
|
$6.34M |
| 3 |
Tenet Healthcare
THC
|
$5.37M |
| 4 |
Amgen
AMGN
|
$4.19M |
| 5 |
Elevance Health
ELV
|
$3.89M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pfizer
PFE
$141B
| $22.3M | 7.29% | 920,000 -5,000 | -0.5% | -$121K |
|
2
Medtronic
MDT
$119B
| $19.5M | 6.38% | 224,000 +19,000 | +9% | +$1.66M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $18.8M | 6.14% | 406,000 -29,000 | -7% | -$1.34M |
|
4
Becton Dickinson
BDX
$55.3B
| $16.9M | 5.52% | 98,000 +16,000 | +20% | +$2.76M |
|
|
5
Merck
MRK
$210B
| $16M | 5.23% | +202,000 | New | +$16M |
|
6
Gilead Sciences
GILD
$140B
| $14.1M | 4.6% | 127,000 -13,000 | -9% | -$1.44M |
|
7
Incyte
INCY
$16.5B
| $13.9M | 4.54% | 204,000 +45,000 | +28% | +$3.06M |
|
|
8
Amgen
AMGN
$155B
| $12.3M | 4.02% | 44,000 -15,000 | -25% | -$4.19M |
|
9
Ionis Pharmaceuticals
IONS
$6.79B
| $11.3M | 3.69% | 285,842 | – | – |
|
10
CVS Health
CVS
$92.8B
| $11.2M | 3.68% | 163,000 -39,000 | -19% | -$2.69M |
|
11
Cardinal Health
CAH
$35.5B
| $11.1M | 3.62% | 66,000 -22,000 | -25% | -$3.7M |
|
|
12
Thermo Fisher Scientific
TMO
$186B
| $10.3M | 3.38% | +25,500 | New | +$10.3M |
|
13
Centene
CNC
$14.3B
| $8.25M | 2.7% | 152,000 -25,000 | -14% | -$1.36M |
|
14
Baxter International
BAX
$12.7B
| $8.12M | 2.65% | 268,007 +20,357 | +8% | +$616K |
|
15
Zimmer Biomet
ZBH
$21B
| $8.08M | 2.64% | 88,631 -25,000 | -22% | -$2.28M |
|
16
Bruker
BRKR
$5.16B
| $8.07M | 2.64% | 195,970 -16,000 | -8% | -$659K |
|
|
17
Elevance Health
ELV
$71.8B
| $7.3M | 2.39% | 18,779 -10,000 | -35% | -$3.89M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.73M | 2.2% | 122,348 -15,000 | -11% | -$825K |
|
19
Biogen
BIIB
$19.4B
| $6.36M | 2.08% | 50,639 +32,000 | +172% | +$4.02M |
|
20
Humana
HUM
$36.5B
| $5.75M | 1.88% | 23,500 -1,500 | -6% | -$367K |
|
21
Qiagen
QGEN
$10.1B
| $5.62M | 1.84% | 117,000 -70,000 | -37% | -$3.36M |
|
22
GE HealthCare
GEHC
$33.7B
| $5.48M | 1.79% | 74,000 +12,000 | +19% | +$889K |
|
|
23
Labcorp
LH
$23.1B
| $5.11M | 1.67% | +19,484 | New | +$5.11M |
|
|
24
Avantor
AVTR
$9.18B
| $5.02M | 1.64% | +372,638 | New | +$5.02M |
|
25
PTC Therapeutics
PTCT
$3.92B
| $4.51M | 1.47% | 92,250 | – | – |
|